Dapoxetine debate and conflict of interest.

摘要

I read "The Dapoxetine Case" article [1] and the enclosed commentaries with great interest. I believe that publishing this article and the debate was right and a good editorial decision.I was a bit surprised by the tone, hostility, and probably naivety of Dr. Hellstrom's response. I have reviewed manuscripts of studies supported by various pharmaceutical companies and many of these articles were biased and ghostwritten (some openly). I do not believe that the rofecoxib (Vioxx) case or some studies with selective serotonin reuptake inhibitors mentioned by Dr. Hellstrom are an exception. I also found the notion suggesting that the journal's impact factor being indirectly linked to the funding from pharmaceutical industry totally out of place in a scientific debate. This notion has nothing to do with the heart of the matter.